These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11276797)

  • 21. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.
    Stacy J; Shaw E; Arledge MD; Howell-Smith D
    J Manag Care Pharm; 2003; 9(4):327-34. PubMed ID: 14613451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
    Knill-Jones RP
    Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)-what makes a NSAID good value for money?
    Freemantle N
    Rheumatology (Oxford); 2000 Mar; 39(3):232-4. PubMed ID: 10788528
    [No Abstract]   [Full Text] [Related]  

  • 27. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.
    Fries JF; Williams CA; Bloch DA; Michel BA
    Am J Med; 1991 Sep; 91(3):213-22. PubMed ID: 1892140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wynne HA; Campbell M
    Pharmacoeconomics; 1993 Feb; 3(2):107-23. PubMed ID: 10146960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care.
    Fendrick AM
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
    James MW; Hawkey CJ
    Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
    Scheiman JM; Fendrick AM
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.
    Rahme E; Barkun AN; Adam V; Bardou M
    Drug Saf; 2004; 27(13):1019-42. PubMed ID: 15471508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
    van Staa TP; Leufkens HG; Zhang B; Smeeth L
    PLoS Med; 2009 Dec; 6(12):e1000194. PubMed ID: 19997499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman A; Ellershaw J
    Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1240-8. PubMed ID: 20955443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.